-
Mashup Score: 1Secukinumab given positive EMA opinion for juvenile arthritis - 2 year(s) ago
Click through for further details on this announcement
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Despite most adverse events of special interest being deemed mild to moderately severe in nature, these types of events have been increasingly reported in real-world practice.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
A new systematic review of secukinumab-induced adverse events determined that the most common events were #IBD, eczematous drug eruption, drug-associated vasculitis, and drug-induced lupus erythematosus. #secukinumab #dermtwitter https://t.co/YaKjws1Ozz
-
-
Mashup Score: 0
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Patients with #psoriaticarthritis receiving #secukinumab had improvement in disease activity after 1 year of treatment, which was maintained or increased at years 2 and 3. https://t.co/uNjyXoyXzQ
-
-
Mashup Score: 2
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
“Rheumatic diseases are extensively managed with bDMARDs, but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient’s decision." #Secukinumab #psoriaticarthritis https://t.co/GNwzObOGDa
-
-
Mashup Score: 0
A notable percentage of patients with rheumatic diseases, such as psoriatic arthritis, stop taking bDMARDs due to lack of effectiveness and adverse events.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
A notable percentage of patients with rheumatic diseases, such as #psoriaticarthritis, stop taking bDMARDs due to lack of effectiveness and adverse events. #Secukinumab https://t.co/aeAeJO5EyG
-
-
Mashup Score: 1The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial - 2 year(s) ago
Secukinumab resulted in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses compared with placebo in patients with active psoriatic arthritis. These improvements were seen irrespective of previous TNF inhibitor use, in a post-hoc analysis. These results indicate that secukinumab provides comprehensive improvement for patients with psoriatic…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
#Secukinumab improves patient-reported outcomes in #PsoriaticArthritis. Full Article https://t.co/Ir7SyYZhS2 and linked comment https://t.co/OfJk3cIHDt https://t.co/jFuUOyJ64m
-
-
Mashup Score: 1Secukinumab improves patient-reported outcomes across all doses in psoriatic arthritis - 2 year(s) ago
Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active psoriatic arthritis, according to data.“Secukinumab was effective in both TNF-naïve and TNF-inadequate-response patients with PsA, offering significant and clinically meaningful improvements in
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active #psoriaticarthritis, said researchers @StanfordMed https://t.co/4QfOZ6sWOK
-
-
Mashup Score: 2The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial - 2 year(s) ago
Secukinumab resulted in early, statistically significant, clinically meaningful, sustained improvements in PROs across all doses compared with placebo in patients with active psoriatic arthritis. These improvements were seen irrespective of previous TNF inhibitor use, in a post-hoc analysis. These results indicate that secukinumab provides comprehensive improvement for patients with psoriatic…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—The effect of #secukinumab on patient-reported outcomes in patients with active #PsoriaticArthritis in the FUTURE 5 randomised phase 3 trial https://t.co/znSfXnvIN5 #LancetRheumatology #PRO https://t.co/wnR9SeTNaO
-
-
Mashup Score: 1
The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and older, and for active enthesitis-related arthritis in those aged 4 years and older.The announcement, issued Dec. 22, makes secukinumab (Cosentyx, Novartis) the first biologic indicated for enthesitis-related arthritis, and the only biologic agent approved for both enthesitis-related
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The #FDA has approved @Novartis' #secukinumab for the treatment of active #psoriaticarthritis in patients aged 2 years and older, and for active enthesitis-related #arthritis in those aged 4 years and older https://t.co/o59lrkP7ZO
-
-
Mashup Score: 0Secukinumab Approved for Pediatric Patients With ERA, PsA - 2 year(s) ago
Secukinumab is approved for use among patients with enthesitis-related arthritis (ERA) aged 4 years and up, and those with psoriatic arthritis (PsA) who are at least 2 years old.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Secukinumab is now approved for use among patients with enthesitis-related arthritis aged 4 years and up, and those with #psoriaticarthritis who are at least 2 years old: https://t.co/yNN67qUxpT https://t.co/6LC0a9jc2w
-
approvalsWatch: EMA recommends approval of #secukinumab for the treatment of juvenile psoriatic arthritis & enthesitis-related arthritis @EMA_news https://t.co/yBe66KuKKf